Collagen signature adds prognostically significant information to staging for breast cancer
- PMID: 39577107
- PMCID: PMC11616558
- DOI: 10.1016/j.esmoop.2024.103990
Collagen signature adds prognostically significant information to staging for breast cancer
Abstract
Background: Tumor-associated collagen signature (TACS) is an independent prognostic factor for breast cancer. However, it is unclear whether the complete collagen signature, including TACS, the TACS-based collagen microscopic features (TCMF1), and the TACS-based nuclear features (TCMF2), can provide additional prognostic information for the current tumor-node-metastasis (TNM) staging system.
Patients and methods: We included 941 patients with breast cancer from three cohorts: the training (n = 355), internal (n = 334), and external validation cohorts (n = 252). TACS and TCMF1 were obtained by multiphoton microscopy (MPM). TCMF2 was extracted on the hematoxylin and eosin images colocated with MPM images. They were linearly combined to establish a complete collagen signature score for reclassifying current TNM staging into stage Ⅰ (II and Ⅲ)/low risk and stage Ⅰ (II and Ⅲ)/high risk.
Results: The low-risk collagen signatures 'downstaged' patients in stage II or Ⅲ, while the high-risk collagen signatures 'upstaged' patients with stage Ⅰ tumors. After incorporating the complete collagen signature into the current TNM staging system, the modified staging system had a higher ability to stratify patients [referent, Ⅰ-new; Ⅱ-new, hazard ratio (HR) 8.655, 6.136, and 4.699 in the training, internal validation, and external validation cohorts, respectively; Ⅲ-new, HR 14.855, 11.201, and 13.245 in the corresponding three cohorts, respectively] than the current TNM staging system (referent, Ⅰ; Ⅱ, HR 1.642, 1.853, and 1.371 in the corresponding three cohorts, respectively; Ⅲ, HR 4.131, 4.283, and 3.711 in the corresponding three cohorts, respectively). Furthermore, the modified staging system showed a higher area under the curve than the current TNM staging system (training cohort: 0.843 versus 0.683; internal validation cohort: 0.792 versus 0.661; and external validation cohort: 0.793 versus 0.646).
Conclusions: The complete collagen signature is an independent predictor of survival outcomes in breast cancer. It adds significant information about the biological behavior of the disease to staging for breast cancer.
Keywords: TNM staging; breast cancer; collagen signature; prognosis.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Figures



Similar articles
-
Computer-assisted quantification of tumor-associated collagen signatures to improve the prognosis prediction of breast cancer.BMC Med. 2021 Nov 18;19(1):273. doi: 10.1186/s12916-021-02146-7. BMC Med. 2021. PMID: 34789257 Free PMC article.
-
Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients.Theranostics. 2021 Jan 1;11(7):3229-3243. doi: 10.7150/thno.55921. eCollection 2021. Theranostics. 2021. PMID: 33537084 Free PMC article.
-
Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.JAMA Netw Open. 2021 Nov 1;4(11):e2136388. doi: 10.1001/jamanetworkopen.2021.36388. JAMA Netw Open. 2021. PMID: 34846524 Free PMC article.
-
Collagen signature as a novel biomarker to predict axillary lymph node metastasis in breast cancer using multiphoton microscopy.J Biophotonics. 2022 Jun;15(6):e202100365. doi: 10.1002/jbio.202100365. Epub 2022 Feb 22. J Biophotonics. 2022. PMID: 35084104
-
Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.Front Immunol. 2022 Mar 23;13:835630. doi: 10.3389/fimmu.2022.835630. eCollection 2022. Front Immunol. 2022. PMID: 35401554 Free PMC article.
Cited by
-
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy.J Hematol Oncol. 2025 Jun 19;18(1):65. doi: 10.1186/s13045-025-01717-y. J Hematol Oncol. 2025. PMID: 40537775 Free PMC article. Review.
-
Outperforming Traditional Staging: A Novel Nomogram for HR-Positive Breast Cancer.Ther Clin Risk Manag. 2025 Feb 25;21:191-208. doi: 10.2147/TCRM.S485685. eCollection 2025. Ther Clin Risk Manag. 2025. PMID: 40028394 Free PMC article.
-
Multimodal tumor microenvironment signature of colorectal cancer for prediction prognosis and chemotherapy benefit.NPJ Precis Oncol. 2025 Aug 2;9(1):270. doi: 10.1038/s41698-025-01069-3. NPJ Precis Oncol. 2025. PMID: 40753305 Free PMC article.
References
-
- Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
-
- Singletary S.E., Allred C., Ashley P., et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83(4):803–819. - PubMed
-
- Weiss A., King T.A., Hunt K.K., et al. Incorporating biologic factors into the American Joint Committee on Cancer breast cancer staging system: review of the supporting evidence. Surg Clin North Am. 2018;98(4):687–702. - PubMed
-
- Cserni G., Chmielik E., Cserni B., et al. The new TNM-based staging of breast cancer. Virchows Arch. 2018;472(5):697–703. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical